STO:BRIGHT — End of Trading in BTA
Jun 24, 2025, 9:59:59 PM UTC
Summary
BrightBid Group AB has announced the end of trading in its BTA (Paid Subscription Option) on June 24, 2025, as part of its planned rights issue. The offering, approved by an extraordinary general meeting, aims to raise approximately 17.7 million SEK for funding ongoing organic growth and product development. The subscription price is set at 0.73 SEK per share, with existing shareholders facing a maximum dilution of about 40%. The rights issue is supported by commitments covering 29.9% of subscriptions and guarantees, which indicates a strong interest from investors. BrightBid Group operates within the adtech sector, offering data-driven traffic generation services through its SaaS products including BrightBid and Bidbrain. This strategy is expected to enhance its market position and expand its operational capabilities.
Company
BrightBid Group (STO:BRIGHT)STO — Technology,
Similar Events
End of Trading in BTA (Paid Subscription Shares)
Irisity AB (publ) has announced the end of trading for its Paid Subscription Shares (BTA) on June 11, 2025. This cessation coincides with the company's ongoing rights issue to raise approximately 21.1 million SEK before expenses, having been approved by an extraordinary general meeting on May 7, 2025. The rights issue, where existing shareholders can subscribe to new shares, could lead to a dilution of about 31.6% for those who do not participate. Irisity specializes in AI-driven solutions for video and camera management systems, with over 3,000 installations worldwide, enhancing real-time data analytics for improved safety and efficiency.
OperationalTrading in Paid Subscribed Shares (BTA) Ends
Initiator Pharma A/S announced that trading in paid subscribed shares (BTA) will conclude on June 27, 2025, on the Nasdaq First North Growth Market. This follows the Company’s rights issue aimed at raising approximately SEK 56.2 million for advancing its lead drug candidate, pudafensine, a Monoamine Reuptake Inhibitor with potential in treating erectile dysfunction and neuropathic pain. The capital raised will primarily fund a clinical trial in vulvodynia, which addresses significant unmet medical needs in women’s health. The rights issue is substantially covered by commitment and guarantee undertakings totaling around SEK 48 million, expected to finance Initiator well into 2027.
Trading in Paid Subscribed Shares (BTA) EndsLast Day of Trading in Paid Subscribed Shares (BTA).
Cell Impact AB announced that July 31, 2025, will be the last day of trading for paid subscribed shares (BTA) as part of its ongoing offering process. This period follows the company’s decision to raise approximately 62.7 million SEK through a rights issue, subject to shareholder approval at an extraordinary general meeting on June 19, 2025. Key details include a subscription price of 0.02 SEK per share and a subscription period from June 26 to July 10, 2025. The funds are intended to support working capital needs as delayed customer orders are expected to materialize in the second half of 2025, facilitating a transition into a planned growth phase.
trading-issue-sharesTrading in BTAs continues.
Initiator Pharma A/S is proceeding with a rights issue aiming to raise approximately SEK 56.2 million to support continued development of its lead candidate, pudafensine, which has shown efficacy in treating erectile dysfunction and has potential applications in treating neuropathic pain and vulvodynia. The rights issue will provide shareholders with subscription rights, and it is supported by commitments amounting to approximately SEK 48 million from existing shareholders, representing 86% of the planned fundraising. Initiator plans to use the proceeds for clinical trials, additional pre-clinical studies, and related corporate purposes, financing its operations into 2027. The subscription period runs from June 10 to June 24, 2025.
Corporate Action